Skip to main content
Access Resources

MJFF Publications

1221 - 1230 of 7574 Results
Title
Year
  • Year
  • 2022
  • 2022
  • 2022
  • 2022
  • 2022
  • 2022
  • 2022
  • 2022
  • 2022
  • 2022
  • RESTRICTED
    Title: Biofluid markers of blood-brain barrier disruption and neurodegeneration in Lewy body spectrum diseases: A systematic review and meta-analysis
    Journal Name: Parkinsonism & Related Disorders
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1016/j.parkreldis.2022.06.004
    Best OA location URL:
    Citation Count: 11
  • RESTRICTED
    Title: Cellular senescence: a key therapeutic target in aging and diseases
    Journal Name: Journal of Clinical Investigation
    Publisher: American Society for Clinical Investigation
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License: cc-by, cc-by
    DOI - Digital Object Identifier: 10.1172/jci158450
    Citation Count: 110
  • RESTRICTED
    Title: Characterization and diagnostic potential of R2* in early-stage progressive supranuclear palsy variants
    Journal Name: Parkinsonism & Related Disorders
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License: cc-by-nc-nd
    DOI - Digital Object Identifier: 10.1016/j.parkreldis.2022.06.021
    Citation Count: 6
  • RESTRICTED
    Title: DARQ: Deep learning of quality control for stereotaxic registration of human brain MRI to the T1w MNI-ICBM 152 template
    Journal Name: NeuroImage
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License: cc-by-nc-nd
    DOI - Digital Object Identifier: 10.1016/j.neuroimage.2022.119266
    Citation Count: 8
  • RESTRICTED
    Title: Diagnosis and treatment of orthostatic hypotension
    Journal Name: The Lancet Neurology
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1016/s1474-4422(22)00169-7
    Citation Count: 46
  • RESTRICTED
    Title: Effect of glycine transporter 1 inhibition with bitopertin on parkinsonism and L-DOPA induced dyskinesia in the 6-OHDA-lesioned rat
    Journal Name: European Journal of Pharmacology
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License: cc-by
    DOI - Digital Object Identifier: 10.1016/j.ejphar.2022.175090
    Citation Count: 6
  • RESTRICTED
    Title: Evidence for immune system alterations in peripheral biological fluids in Parkinson's disease
    Journal Name: Neurobiology of Disease
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License: cc-by
    DOI - Digital Object Identifier: 10.1016/j.nbd.2022.105744
    Citation Count: 15
  • RESTRICTED
    Title: Genome Sequencing in the Parkinson Disease Clinic
    Journal Name: Neurology Genetics
    Publisher: Ovid Technologies (Wolters Kluwer Health)
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License: cc-by-nc-nd
    DOI - Digital Object Identifier: 10.1212/nxg.0000000000200002
    Citation Count: 8
  • RESTRICTED
    Title: Glutamate modulation for the treatment of levodopa induced dyskinesia: a brief review of the drugs tested in the clinic
    Journal Name: Neurodegenerative Disease Management
    Publisher: Informa UK Limited
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.2217/nmt-2021-0055
    Best OA location URL:
    Citation Count: 6
  • RESTRICTED
    Title: Immune aging in multiple sclerosis is characterized by abnormal CD4 T cell activation and increased frequencies of cytotoxic CD4 T cells with advancing age
    Journal Name: eBioMedicine
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License: cc-by-nc-nd
    DOI - Digital Object Identifier: 10.1016/j.ebiom.2022.104179
    Citation Count: 19
Filters
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.